1211. Staphylococcus aureus Vaccines
Session: Symposium: Vaccine-Preventable Healthcare-Associated Infections
Friday, October 19, 2012: 2:00 PM
Room: SDCC 29 ABCD
Michael Otto, PhD, FSHEA; National Institute of Allergy and Infectious Diseases/National Institutes of Health, National Institute of Allergy and Infectious Diseases/National Institute of Health, Hamilton, MT

Date and place of birth:
June 30th, Sindelfingen, Germany
Nationality: German, US Permanent resident
Address:
Laboratory of Human Bacterial Pathogenesis
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Bldg. 33, 1W10
9000 Rockville Pike, Bethesda, MD 20892
Phone: 301-443-5209
Email: motto@niaid.nih.gov
Education:
M.S. (Diplom), Biochemistry, University of Tübingen, Germany, June 1992

Ph.D., Microbiology, University of Tübingen, Germany, Jan 1998
Thesis title: “Epidermin: Biochemische Untersuchungen zur Biosynthese, Regulation und Immunität” (Epidermin: Biochemical investigation of biosynthesis, regulation, and immunity)
Mentor: Friedrich Götz, Ph.D.
Post-doctoral training, Staphylococcus epidermidis and Staphylococcus aureus biofilm formation and gene regulation, Department of Microbiology, University of Tübingen, Germany, Feb 1998 - Dec 2000.
Mentor: Friedrich Götz, Ph.D.
Tenure-Track Investigator, Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, NIAID, NIH, July 2001-September 2007
Current position:
Senior Investigator, Laboratory of Human Bacterial Pathogenesis, NIAID, NIH, Bethesda, MD, since October 2007
Professional experience:
1993-1997 Graduate Teaching Assistant, Microbiology, University of Tübingen
1998-2000 Postdoctoral Teaching Assistant, Microbiology, University of Tübingen
2001-2007 Principal Investigator, NIAID, NIH, Hamilton, MT
2007-2008 Senior Investigator, NIAID, NIH, Hamilton, MT
2008 Senior Investigator, NIAID, NIH, Bethesda, MD



Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.